Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma in Populations of African Descent.
Chang-Wolf JM, Kinzy TG, Driessen SJ, Cruz LA, Iyengar SK, Peachey NS, Aung T, Khor CC, Williams SE, Ramsay M, Olawoye O, Ashaye A, Klaver CCW, Hauser MA, Thiadens AAHJ, Cooke Bailey JN, Bonnemaijer PWM; Genetics in Glaucoma Patients of African Descent (GIGA) Study GroupGenetics of Glaucoma in People of African Descent (GGLAD) Study GroupMillion Veteran Program (MVP). Chang-Wolf JM, et al. JAMA Ophthalmol. 2024 Nov 14:e244784. doi: 10.1001/jamaophthalmol.2024.4784. Online ahead of print. JAMA Ophthalmol. 2024. PMID: 39541127
Star-shaped TDP-43 inclusions in the oldest-old.
Connolly EE, Ervin JF, Plassman BL, Welsh-Bohmer KA, Wang SJ. Connolly EE, et al. Among authors: ervin jf. J Neuropathol Exp Neurol. 2024 Nov 4:nlae116. doi: 10.1093/jnen/nlae116. Online ahead of print. J Neuropathol Exp Neurol. 2024. PMID: 39495967 No abstract available.
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Klinkardt U, Schunk M, Ervin J, Schindler C, Sugimoto D, Rankin B, Amann R, Monti M, Kutschenko A, Schumacher C, Huber K, Zeder A, Heikkila N, Didierlaurent AM, Schwarz SE, Derouazi M. Klinkardt U, et al. Among authors: ervin j. Hum Vaccin Immunother. 2024 Dec 31;20(1):2410574. doi: 10.1080/21645515.2024.2410574. Epub 2024 Oct 14. Hum Vaccin Immunother. 2024. PMID: 39397784 Free PMC article. Clinical Trial.
Author Correction: A policy-driven framework for conserving the best of Earth's remaining moist tropical forests.
Hansen AJ, Burns P, Ervin J, Goetz SJ, Hansen M, Venter O, Watson JEM, Jantz PA, Virnig ALS, Barnett K, Pillay R, Atkinson S, Supples C, Rodríguez-Buritica S, Armenteras D. Hansen AJ, et al. Among authors: ervin j. Nat Ecol Evol. 2024 Sep 13. doi: 10.1038/s41559-024-02557-8. Online ahead of print. Nat Ecol Evol. 2024. PMID: 39271937 No abstract available.
Assessing patient autonomy in the context of TeamBirth, a quality improvement intervention to improve shared decision-making during labor and birth.
Neergheen VL, Chaer LE, Plough A, Curtis E, Paterson VJ, Short T, Bright A, Lipsitz S, Murphy A, Miller K, Subramanian L, Radichel E, Ervin J, Castleman L, Brown E, Yeboah T, Simas TM, Terk D, Vedam S, Shah N, Weiseth A. Neergheen VL, et al. Among authors: ervin j. Birth. 2024 Dec;51(4):855-866. doi: 10.1111/birt.12857. Epub 2024 Aug 14. Birth. 2024. PMID: 39140579
Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, Hulstrøm V. Schwarz TF, et al. Among authors: ervin je. J Infect Dis. 2024 Jul 25;230(1):e102-e110. doi: 10.1093/infdis/jiad546. J Infect Dis. 2024. PMID: 39052726 Free PMC article. Clinical Trial.
Internal and external spatial analysis of trace elements in local crayfish.
Kazery JA, Garteiser JW, Cockrell CM, Doubert AD, Ervin JE, Brown MS, Burns KE, Hearst SM. Kazery JA, et al. Among authors: ervin je. Environ Technol. 2024 Jul 17:1-14. doi: 10.1080/09593330.2024.2380396. Online ahead of print. Environ Technol. 2024. PMID: 39016240
Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
Falsey AR, Hosman T, Bastian AR, Vandenberghe S, Chan EKH, Douoguih M, Heijnen E, Comeaux CA, Callendret B; CYPRESS investigators. Falsey AR, et al. Lancet Infect Dis. 2024 Sep;24(9):1015-1024. doi: 10.1016/S1473-3099(24)00226-3. Epub 2024 May 24. Lancet Infect Dis. 2024. PMID: 38801826 Clinical Trial.
158 results